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Abstract
HIV-associated anal carcinoma, a non-AIDS-defining cancer, is a human papillomavirus-associated
malignancy with a spectrum of preinvasive changes. The standardized incidence ratio for anal cancer
in patients with HIV/AIDS is 20-50. Algorithms for anal cancer screening include anal cytology
followed by high-resolution anoscopy for those with abnormal findings. Outpatient topical treatments
for anal intraepithelial neoplasia include infrared coagulation therapy, trichloroacetic acid, and
imiquimod. The development of cost-effective national screening programs for HIV-associated anal
cancer remains a challenge.
Introduction and context
Within 5 years of the beginning of the human immuno-
deficiency virus (HIV)-1 pandemic in 1981, Kaposi’s
sarcoma and non-Hodgkin’s lymphoma had been classi-
fied as AIDS-defining illnesses, and invasive cervical
cancer was added to this list in 1993. The introduction
of highly active antiretroviral therapy (HAART) in the
late 1990s transformed the care of patients with HIV and
led to an overall fall in the incidence of AIDS-defining
cancers [1,2]. It is now recognized that there is a higher
incidence of a number of other malignancies, including
anal carcinoma, in HIV-infected patients. Anal cancer has
many parallels with cervical carcinoma in that human
papillomavirus (HPV) infection is the causative factor
in nearly all cases, and there is a spectrum of anal
precancerous changes, referred to as anal intraepithelial
neoplasia (AIN). However, the typically late clinical
presentation of anal cancer, morbidity of treatments for
invasive disease, and high relapse rates indicate that
effective early detection and treatment of preinvasive
disease are of considerable importance.
Incidence and risk of anal cancer
Prior to the HIV epidemic, it was known that anal
carcinoma was more common in men who have sex with
men (MSM) than in the general population [3]; however,
anal carcinoma is currently at least twice as common
in HIV-positive MSM as in HIV-negative MSM [4]. The
standardized incidence ratio (SIR) of anal carcinoma
in people with HIV/AIDS is between 19 and 50 [5]. In
the Chelsea and Westminster Hospital cohort of
6127 HIV patients, the incidence of anal squamous
carcinoma was 141 per 106 patients per annum [6], and
the prevalence is rising as a consequence of increased
longevity [6,7].
Unlike in AIDS-defining cancer, there has been no
decline in SIR in the post-HAART era [6]. The risk of
anal cancer was initially reported to be unrelated to CD4
cell count [8], although more recently others have
identified an increased incidence at lower CD4 levels
[7,9]. In a recent meta-analysis, patients immunosup-
pressed following organ transplant had an SIR for anal
cancer of 4.85 whereas the SIR for those with HIV/AIDS
was 28.75, reflecting the higher exposure to oncogenic
HPV in the latter group [5].
People with a longer duration ofHIV infection (>15 years)
have a 12-fold higher rate of anal cancer than those that
have been infected for less than 5 years [10]. Because the
life expectancy of the HIV-positive population continues
to increase and because HAART does not appear to be
protective, preventative strategies against anal cancer are
needed.
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Natural history of anal cancer
HPV is a common sexually transmitted infection, with
prevalence rates of 50-60% for anal HPV infection in HIV-
negative MSM across all age groups [11]. Anal cancer
probably arises because of HPV infection of metaplastic
reserve cells within the transformation zone, the junction
of the anal squamous and rectal columnar epithelia. Anal
dysplasia can be classified according to the Richart grading
scale (AIN) [12] or the Bethesda system (low-grade
squamous intraepithelial lesion/high-grade squamous
intraepithelial lesion, or LSIL/HSIL) [13] (Figure 1).
The natural history of anal cancer is not fully understood.
Studies of HIV-negative MSM found the rates of pre-
valence of LSIL and HSIL to be 15% and 5%, respectively
[14]. There is a very high prevalence (25-50%) of high-
grade AIN in HIV-positive MSM [15-17]. The exact
frequency of progression from AIN III to anal cancer is
not known, although a figure of between 1% and 8% is
estimated [18-21]. Treatment of HSIL appears to be
associated with a lower rate of progression to invasive
disease [20].
Protocols for screening for anal cancer
Given that AIN II/III is the likely precursor of anal cancer
and given the parallels in natural history with cervical
cancer, a screening program has been suggested (Figure 2)
[22,23]. High-resolution anoscopy (HRA) is a technique
to directly identify and treat anal dysplasia. The technique
is analogous to colposcopy and is used because AIN
severity can be established only after histopathologic
assessment via biopsy.
The effectiveness of cytological screening has been
studied by comparing the results of cytology smears
and histology from HRA-directed biopsies. A sensitivity
of 69-93% and a specificity of 32-59% were reported in
one review [24], and a Chelsea and Westminster
Hospital cohort of 99 patients found a sensitivity of
83% and a specificity of 38% [25].
Recent advances
Infrared coagulation therapy
Infrared (IR) coagulation therapy has been used success-
fully to treat a variety of lesions, including condylomas
and benign cervical disease. It is employed in the
outpatient setting and only local anesthesia is required.
More recently, IR coagulation has been used in the
treatment of high-grade anal dysplasia [26-28]. With
follow-up between 6 and 14 months, response rates
ranged from 35% to 63%. The procedure was well
tolerated, only mild/moderate anal pain was reported,
and bleeding was the most common side effect.
Imiquimod
Imiquimod was originally licensed for the treatment of
external genital condyloma and is an immunomodulator
that signals through Toll-like receptor 7 to induce
inflammation through activation of the innate and
adaptive immune response. Although imiquimod is not
licensed for use in or around the anus, three recent studies
have shown it to be effective and well tolerated [29-31].
And although the duration of follow-up was no more
Figure 1. The Richart and Bethesda classification of anal dysplastic changes
AIN, anal intraepithelial neoplasia.
Figure 2. Suggested screening algorithm for anal cancer
AIN, anal intraepithelial neoplasia; HRA, high-resolution anoscopy. Adapted
from [23].
Page 2 of 5
(page number not for citation purposes)
F1000 Medicine Reports 2010, 2:85 http://f1000.com/reports/m/2/85
than 9 months in two of the reports, response rates were
reasonable, ranging from 46% to 74%. Sanclemente et al.
[31] described a 29% recurrence rate; however, in the only
other study to report recurrence rates (58%), all of these
were found in previously untreated sites [30].
Trichloroacetic acid
Trichloroacetic acid (TCA) is widely used in the
treatment of superficial skin lesions. In a nonrando-
mized comparison of TCA with IR coagulation therapy
to treat HSIL in HIV-positive MSM, there was an 87%
clearance rate with TCA at 13-month follow-up com-
pared with 68% with IR coagulation [32]. More recently,
Singh and colleagues [33] found that in HIV-positive
men with one lesion, 48% showed clearance following
TCA treatment in comparison with just 18% with four or
more lesions. Topical 85% TCA was found to be both
safe and well tolerated.
Other treatments
The quadrivalent prophylactic HPV vaccine, Gardasil
(Merck & Co., Inc., Whitehouse Station, NJ, USA), is
licensed for the prevention of HPV-associated cancers in
women and for the prevention of genital warts in males
and females. In a cohort of more than 4000 healthy men
from 16 to 26 years of age, quadrivalent HPV vaccination
resulted in an 85.6% efficacy against HPV 6/11/16/18-
related persistent infection and DNA detection, with a
favorable safety profile [34].
Implications for clinical practice
Screening programs for anal cancer
Advances in the accurate diagnosis and treatment of AIN
raise the possibility of the introduction of national
screening programs. In the American health-care system,
screening HIV-positive MSM every 2 years with anal
cytology would offer quality-adjusted life expectancy
benefits at a cost per quality-adjusted life year (QALY)
of $13,000, which is comparable to other established
screening programs [35]. In contrast, anal screening
appears to be much less cost-effective in the UK National
Health Service model, in which increased low-grade AIN
regression rates were found to result in a minimum
incremental cost per QALY of £39,405 (approximately
$61,555) [36].
National guidelines
Although recommendations exist for anal cancer screen-
ing, the paucity of clinicians with expertise in HRA has
limited the introduction of screening guidelines for at-
risk patient populations. Important questions that need
to be answered prior to widespread screening include the
impact of treatment on the natural progression of HSIL
of the anus to invasive disease and whether biomarkers
can be found to identify which patients with HSIL will go
on to develop invasive cancer.
The degree of uncertainty regarding the benefits and cost-
effectiveness of anal screening is reflected in the various
professional recommendations. Guidelines produced
jointly between the British HIV Association, the British
Association for Sexual Health and HIV, and the Faculty
of Family Planning and Reproductive Healthcare (2007)
[37] state “the role of annual anal cytology and HRA is
not yet proven; however, patients should be encouraged
to check to report any lumps noticed in the anal canal
(evidence level IV)”.
In contrast, the New York State Department of Health
AIDS Institute (2007) [38] suggests “screening for
cellular dysplasia is prudent and recommended, parti-
cularly in persons at high risk for infection with
papilloma virus” (HIV-positive MSM and those with
anal warts). It is estimated that this would apply to 52%
of the male HIV-positive population, of which less than
30% would require HRA.
The European Aids Clinical Society guidelines (2009) [39]
recommend screening every 1-3 years with digital rectal
examination with or without anal cytology, with HRA
reserved for those with abnormal cytology. It is acknowl-
edged that the evidence for benefit of screening is
unknown but that screening is advocated by some experts.
The Centre for Disease Control and Infection guidelines
(2009) [40] acknowledge the potential benefits of
cytology screening but state that “studies of screening
and treatment programs for AIN 2 or 3 should be
implemented before definitive recommendations for anal
cytology screening can be made”. However, it is suggested
that if anal cytology has indicated LSIL or HSIL, HRA
should follow.
Conclusion
Anal cancer is an increasing problem in the management
of patients with HIV. Through better understanding of
the natural history of the disease, improvements in
management of AIN, and judicious use of screening
programs, the prognosis for this disease should continue
to improve. History supports this ideal: in the 1980s, the
2-year survival for anal cancer was just 32%, by the mid-
1990s it had risen to 54%, and by the end of the
millennium it was 76%, which is comparable to that in
the HIV-negative population [41].
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